ImmuCell
Regulatory Roadblock: ImmuCell Pivots to Core Growth After FDA Rejects Mastitis Treatment
In a significant strategic shift that marks the end of a multi-year regulatory odyssey, ImmuCell Corporation (Nasdaq: ICCC) announced late yesterday, December 23, 2025, that it has received another Technical Section Incomplete Letter from the U.S. Food and Drug Administration (FDA) regarding its subclinical mastitis treatment, Re-Tain. The letter,